Dr. Maryam Lustberg, MD, MPH
Director of the Center for Breast Cancer at Smilow Cancer Center and Yale Cancer Center.
Dr. Maryam Lustberg is a renowned physician and researcher in the field of breast cancer care. She is currently the Director of the Center for Breast Cancer and the Chief of Breast Medical Oncology at Smilow Cancer Center and Yale Cancer Center, as well as an Associate Professor of Internal Medicine at Yale University School of Medicine. Dr. Lustberg completed her Medical Oncology and Breast Cancer fellowships at The Ohio State University Comprehensive Cancer Center (OSUCCC), where she also obtained an MPH degree in clinical investigation with a focus on clinical translational research in breast cancer.
As Director of the Breast Center at Yale and Chief of Breast Medical Oncology, Dr. Lustberg oversees all aspects of the breast therapeutics program and leads the Breast Disease Research Trials Program. She has extensive experience leading all-phase clinical trials and manages a diverse trial portfolio for the Yale Breast Program. Her research focuses on identifying novel genomic predictors as well as blood and imaging biomarkers for treatment toxicity and survivorship management. Dr. Lustberg is currently the co-Chair of the Alliance Symptom Intervention Committee and the Chair of the Multinational Association of Supportive Care in Cancer (MASCC) Neurological Complications Committee, as well as President-Elect of MASCC.
Dr. Lustberg’s research projects are supported by several grants from the National Cancer Institute and the National Institute of Health, including a current project on the prevention of paclitaxel-induced peripheral neuropathy with nilotinib (5R01CA238946), and a recent project on the effect of N-3 fatty acids and sugars on chemotherapy-induced cognitive deficits (5R01CA189947-04). She has also worked on several other research projects in the area of cancer symptom management and survivorship.
In addition to her research, Dr. Lustberg is actively involved in national organizations that evaluate current guidelines in survivorship and evaluate the newest concepts that will lead to future clinical trials. She is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, the Multinational Associate of Supportive Care in Cancer, and the Alliance for Clinical Trials in Oncology. Dr. Lustberg has received several honors for her work, including the ASCO Young Investigator Award and the Castle Connolly’s Exceptional Women in Medicine Award for 2019.
Dr. Lustberg’s contributions to science include her extensive experience in the conduct of clinical trials in symptom management, specifically in breast cancer survivorship and symptom management. Her research focuses on understanding the biological mechanisms that promote the toxicities experienced by survivors, identifying predictive markers of chemotherapy efficacy and toxicity, and developing innovative clinical/translational trials in breast cancer survivorship and symptom management. Dr. Lustberg actively collaborates with lab-based scientists and bioinformatics specialists in the area of blood-based cancer biomarkers and genomic predictors.
To learn more about Dr. Lustberg’s research, publications, and professional appointments, please visit her Bibliography page on our website. We also have pages dedicated to medical advisors, diagnoses, treatments, and survivor blogs that you may find helpful.